Scientific Sessions 2025  /  Viral Controversies in Heart Failure, Cardiomyopathy, and Cardio-Oncology  /  Risky Business (CON): Can Immunotherapy Be Outlawed in Heart Transplant Patients?
Logo

American Heart Association

  34
  0

Final ID:

Risky Business (CON): Can Immunotherapy Be Outlawed in Heart Transplant Patients?

  • Cheng, Richard  ( University of Washington , Seattle , Washington , United States )
  • Vucicevic, Darko  ( UCLA , Los Angeles , California , United States )
  • Shahandeh, Negeen  ( UCLA , Los Angeles , California , United States )
  • Kopecky, Benjamin  ( University of Colorado , Aurora , Colorado , United States )
    • Author Disclosures:
    Richard Cheng: DO NOT have relevant financial relationships | Darko Vucicevic: No Answer | Negeen Shahandeh: No Answer | Benjamin Kopecky: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Viral Controversies in Heart Failure, Cardiomyopathy, and Cardio-Oncology

Saturday, 11/08/2025 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
Curbing Anthracycline Toxicity (CON): Dexrazoxane is Not for Everyone

Yu Anthony, Levenson Joshua, Kondapalli Lavanya, Dent Susan

Ironing Out Infection Risk (CON): IV Iron is More Help Than Harm

Beavers Craig, Gale Stormi, Bagnola Aaron, Mcilvennan Colleen, Peters Laura

More abstracts from these authors:
Cardiac Allograft Vasculopathy Involves Vascular Remodeling Beyond the Coronary Arteries

Hyacinth Sariah, Dun Hao, Sticco-ivins Maura, Bonnici Gianni, Nelson Samantha, Kopecky Benjamin

Discussant: CAVIAR

Kobashigawa Jon, Lavine Kory, Kopecky Benjamin

You have to be authorized to contact abstract author. Please, Login
Not Available